Natera (NTRA) Receives a Rating Update from a Top Analyst

Cowen & Co. analyst Doug Schenkel maintained a Buy rating on Natera (NTRA) today and set a price target of $30. The company’s shares closed yesterday at $20.63.

According to, Schenkel is a top 100 analyst with an average return of 26.4% and a 70.9% success rate. Schenkel covers the Healthcare sector, focusing on stocks such as Pacific Biosciences, Guardant Health Inc, and NanoString Tech.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $30.80 average price target, a 49.3% upside from current levels. In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $27 price target.


See today’s analyst top recommended stocks >>

Based on Natera’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $33.82 million. In comparison, last year the company had a GAAP net loss of $27.12 million.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception, and Non-Invasive Paternity Testing.